Kevin J. O'SUllivan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kevin J. O'SUllivan has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Aidan G. O’sullivan
Design Factors Research Group, School of Design, University of Limerick, Limerick, Ireland
1 shared publication- Aidan O'SUllivan
Rapid Innovation Unit, Confirm Centre for Smart Manufacturing, Health Research Institute, University of Limerick, Limerick, Ireland
1 shared publication - Alice Shannon
Rapid Innovation Unit - School of Design and Confirm Smart Manufacturing Centre, University of Limerick, Ireland; Health Research Institute, University of Limerick, Ireland
1 shared publication Barry Linnane
Graduate Entry Medical School and Centre for Interventions in Infection, Inflammation & Immunity (4i), University of Limerick, Limerick, Ireland
1 shared publicationCallum Guttridge
Rapid Innovation Unit - School of Design and Confirm Smart Manufacturing Centre, University of Limerick, Ireland; Health Research Institute, University of Limerick, Ireland
1 shared publication- Colum Dunne
School of Medicine and Centre for Interventions in Infection, Inflammation, and Immunity (4i), University of Limerick, Limerick, Ireland
1 shared publication
Latest Publications
- Open Access
- 20 May 2024
- Published by Elsevier in Journal of the Mechanical Behavior of Biomedical Materials
- Vol. 156, 106585
Effects of post-curing duration on the mechanical properties of complex 3D printed geometrical parts
- 20 May 2024
- Published by Elsevier in Journal of the Mechanical Behavior of Biomedical Materials
- Vol. 156, 106585
Open AccessEffects of post-curing duration on the mechanical properties of complex 3D printed geometrical parts
- Open Access
- 24 January 2018
- Published by BMJ in BMJ Innovations
- Vol. 4 (1) , 29-31
Use of 3D printing to create a bespoke repair of a Percutaneous Endoscopic Gastrostomy (PEG) tube in patient unfit for surgical replacement
We report a case of three-dimensional (3D) printing being used to solve a difficult bedside clinical problem and avoidance of substantial risk associated with alternative solutions. A 15-year-old male with advanced cystic fibrosis developed a small (~1mm) linear tear in his Percutaneous Endoscopic Gastrostomy (PEG) tube, approximately 40 mm from the skin surface. The patient’s advanced condition precluded replacement of the PEG tube under general anaesthetic. Attempts to manage the tear with adhesive tapes yielded limited success. 3D printing was used to create a bespoke sealing device overnight, rectifying the leak and allowing enteral feeding to recommence unimpeded. The device is functioning well, several months post-discharge of the patient.
- 24 January 2018
- Published by BMJ in BMJ Innovations
- Vol. 4 (1) , 29-31
Open AccessUse of 3D printing to create a bespoke repair of a Percutaneous Endoscopic Gastrostomy (PEG) tube in patient unfit for surgical replacement
We report a case of three-dimensional (3D) printing being used to solve a difficult bedside clinical problem and avoidance of substantial risk associated with alternative solutions. A 15-year-old male with advanced cystic fibrosis developed a small (~1mm) linear tear in his Percutaneous Endoscopic Gastrostomy (PEG) tube, approximately 40 mm from the skin surface. The patient’s advanced condition precluded replacement of the PEG tube under general anaesthetic. Attempts to manage the tear with adhesive tapes yielded limited success. 3D printing was used to create a bespoke sealing device overnight, rectifying the leak and allowing enteral feeding to recommence unimpeded. The device is functioning well, several months post-discharge of the patient.
- 5 October 2015
- Published by Springer Nature in Annals of Biomedical Engineering
- Vol. 44 (2) , 497-507
Shrinking the Supply Chain for Implantable Coronary Stent Devices
Stenting treatments for the management of disease in the heart, arterial and venous systems, biliary ducts, urethras, ureters, oesophageal tract and prostate have made enormous technical advances since their introduction into clinical use. The progression from metallic to polymer based bio-absorbable stents, coupled with the advances in additive manufacturing techniques, present a unique opportunity to completely re-envision the design, manufacture, and supply chain of stents. This paper looks at current stenting trends and proposes a future where the stent supply chain is condensed from ~150 days to ~20 min. The Cardiologist therefore has the opportunity to become a designer, manufacturer and user with patients receiving custom stents specific to their unique pathology that will be generated, delivered and deployed in the Cath-lab. The paper will outline this potentially revolutionary development and consider the technical challenges that will need to be overcome in order to achieve these ambitious goals. A high level overview of the generating eluting stents in situ program—GENESIS—is outlined including some early experimental work.
- 5 October 2015
- Published by Springer Nature in Annals of Biomedical Engineering
- Vol. 44 (2) , 497-507
Shrinking the Supply Chain for Implantable Coronary Stent Devices
Stenting treatments for the management of disease in the heart, arterial and venous systems, biliary ducts, urethras, ureters, oesophageal tract and prostate have made enormous technical advances since their introduction into clinical use. The progression from metallic to polymer based bio-absorbable stents, coupled with the advances in additive manufacturing techniques, present a unique opportunity to completely re-envision the design, manufacture, and supply chain of stents. This paper looks at current stenting trends and proposes a future where the stent supply chain is condensed from ~150 days to ~20 min. The Cardiologist therefore has the opportunity to become a designer, manufacturer and user with patients receiving custom stents specific to their unique pathology that will be generated, delivered and deployed in the Cath-lab. The paper will outline this potentially revolutionary development and consider the technical challenges that will need to be overcome in order to achieve these ambitious goals. A high level overview of the generating eluting stents in situ program—GENESIS—is outlined including some early experimental work.